Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > Validation for PDCs

<< Previous

Bullboard Posts

Next >>

Comment by Trogarzonon Mar 28, 2023 7:54pm

82 Views

Post# 35365796

RE:RE:Validation for PDCs

Another club of vote my salery and I'l vote yours. Shure would like to have an small idea of what they've accomplished for us in the last 3 years. I remember our Charwoman telling us in 2018 when our dog passed the 1 Biliion valuation and she joyfully declared she would be working on the second billion of market cap. She would probably defend herself by telling us she did so only in reverse.

<< Previous

Bullboard Posts

Next >>

Who, why, and what of the great "Crypto Surge"